Companies Dominating the Vulvar And Vaginal Atrophy (Vva) Therapy Landscape
- Daré Bioscience, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Almirall, S.A.
- Viveve, Inc.
- Lutronic Corporation
- Venus Concept
- ThermiGen, LLC
- Alma Lasers LTD.
- BTL
- Fotona d.o.o.
- TherapeuticsMD, Inc.
Browse Key Market Insights with Data Illustration:
In the News
-
Dare Bioscience, Inc. has announced the initiation of the DARE-VVA1’s Phase I/II trial to evaluate a proprietary investigational formulation for the non-hormonal treatment of moderate to severe vulvar and vaginal atrophy (VVA). DARE-VVA1 is a new intravaginal tamoxifen product developed to treat vulvar and vaginal atrophy.
-
TherapeuticsMD, Inc. announced the approval by the U.S. Food and Drug Administration for Imvexxy 4 mcg dose. Imvexxy 4 mcg is now a commercially available drug in the United States for the treatment of dyspareunia, which is a symptom of vulvar and vaginal atrophy.
